Spiramycin Disarms <i>Pseudomonas aeruginosa</i> without Inhibiting Growth

Spiramycin is a 16-membered macrolide antibiotic currently used in therapy to treat infections caused by Gram-positive bacteria responsible for respiratory tract infections, and it is also effective against some Gram-negative bacteria and against <i>Toxoplasma</i> spp. In contrast, <i...

Full description

Saved in:
Bibliographic Details
Main Authors: Matteo Calcagnile (Author), Inès Jeguirim (Author), Salvatore Maurizio Tredici (Author), Fabrizio Damiano (Author), Pietro Alifano (Author)
Format: Book
Published: MDPI AG, 2023-03-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Spiramycin is a 16-membered macrolide antibiotic currently used in therapy to treat infections caused by Gram-positive bacteria responsible for respiratory tract infections, and it is also effective against some Gram-negative bacteria and against <i>Toxoplasma</i> spp. In contrast, <i>Pseudomonas aeruginosa</i>, which is one of the pathogens of most concern globally, is intrinsically resistant to spiramycin. In this study we show that spiramycin inhibits the expression of virulence determinants in <i>P. aeruginosa</i> in the absence of any significant effect on bacterial multiplication. In vitro experiments demonstrated that production of pyoverdine and pyocyanin by an environmental strain of <i>P. aeruginosa</i> was markedly reduced in the presence of spiramycin, as were biofilm formation, swarming motility, and rhamnolipid production. Moreover, treatment of <i>P. aeruginosa</i> with spiramycin sensitized the bacterium to H<sub>2</sub>O<sub>2</sub> exposure. The ability of spiramycin to dampen the virulence of the <i>P. aeruginosa</i> strain was confirmed in a <i>Galleria mellonella</i> animal model. The results demonstrated that when <i>G. mellonella</i> larvae were infected with <i>P. aeruginosa,</i> the mortality after 24 h was >90%. In contrast, when the spiramycin was injected together with the bacterium, the mortality dropped to about 50%. Furthermore, marked reduction in transcript levels of the antimicrobial peptides gallerimycin, gloverin and moricin, and lysozyme was found in <i>G. mellonella</i> larvae infected with <i>P. aeruginosa</i> and treated with spiramycin, compared to the larvae infected without spiramycin treatment suggesting an immunomodulatory activity of spiramycin. These results lay the foundation for clinical studies to investigate the possibility of using the spiramycin as an anti-virulence and anti-inflammatory drug for a more effective treatment of <i>P. aeruginosa</i> infections, in combination with other antibiotics.
Item Description:10.3390/antibiotics12030499
2079-6382